je.st
news
Home
› Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease
Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease
2014-11-05 05:46:07| drugdiscoveryonline Home Page
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease
Tags: with
study
eye
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|